EHS
EHS

Darzalex Approved to Treat Newly Diagnosed MM Patients

The FDA approved daratumumab (Darzalex, Janssen) in combination with VMP (bortezomib [Velcade, Millennium], melphalan and prednisone) for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for an autologous hematopoietic cell transplant.
EHS
Back to top button